[Ocular hypertension and glaucoma: the contribution of large studies to daily practice].

青光眼 医学 高眼压 眼压 临床试验 正常眼压性青光眼 开角型青光眼 验光服务 眼科 指南 视野 临床实习 重症监护医学 物理疗法 内科学 病理
作者
Alain M. Bron
出处
期刊:Le Centre pour la Communication Scientifique Directe - HAL - Diderot 卷期号:25 (6): 641-54 被引量:3
标识
摘要

Official guidelines to manage and treat various clinical presentations of glaucoma and ocular hypertension are not currently in wide use. Several well-designed clinical trials have been published recently which can provide ophthalmologists with therapeutic recommendations. In the field of ocular hypertension, three major and historic studies are reported and discussed in this review. A more recent study undertaken in Sweden and the design of the Ocular Hypertension Treatment Study (OHTS) are reviewed as well, although the final results of this important trial have not yet been published. The conclusions of the Collaborative Normal Tension Study Group (CNTSG) have been expected for a long time since this disease is difficult to manage; a 30% reduction in baseline intraocular pressure avoids further deterioration of the visual field in most patients. Other studies have dealt with different strategies in open angle glaucoma. The Advanced Glaucoma Intervention Study (AGIS) has investigated different therapeutic sequences in advanced glaucoma while the Collaborative Initial Glaucoma Treatment Study (CIGTS) and the Early Manifest Glaucoma Trial (EMGT), still in progress, have evaluated the efficacy and safety of surgery versus medical treatment and treatment versus no treatment, respectively, in new and low-grade glaucoma. These long-term studies have led to a better approach to ocular hypertension, normal tension glaucoma, initial glaucoma, and advanced glaucoma. This review presents the characteristics of these clinical studies, points out the problems linked to giving a fair and practical interpretation, and attempts to draw useful guidelines for daily clinical practice.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
2秒前
夏尔发布了新的文献求助10
3秒前
aw完成签到,获得积分10
4秒前
miaoli0116完成签到,获得积分10
5秒前
pyrene完成签到 ,获得积分10
5秒前
sciscisci完成签到,获得积分10
6秒前
6秒前
7秒前
hp发布了新的文献求助10
7秒前
我学个P完成签到,获得积分10
8秒前
8秒前
wen完成签到,获得积分10
8秒前
陈心茹完成签到 ,获得积分10
9秒前
stooi完成签到,获得积分10
10秒前
11秒前
12秒前
Gloria2023发布了新的文献求助10
13秒前
13秒前
Yi完成签到,获得积分10
15秒前
15秒前
16秒前
17秒前
Rocky_Qi完成签到,获得积分10
18秒前
Glufo发布了新的文献求助10
18秒前
大个应助yun采纳,获得10
18秒前
身处人海完成签到,获得积分10
18秒前
HJJ完成签到,获得积分10
19秒前
松松完成签到,获得积分10
20秒前
张三完成签到,获得积分10
20秒前
22秒前
松松发布了新的文献求助10
22秒前
纯情的雨雪完成签到,获得积分10
22秒前
风趣的青发布了新的文献求助10
23秒前
斯文败类应助熙熙采纳,获得10
24秒前
Bizi完成签到,获得积分10
24秒前
24秒前
Nexus应助zhou采纳,获得20
24秒前
Lee完成签到,获得积分10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
University Physics for the Life Sciences 500
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6955098
求助须知:如何正确求助?哪些是违规求助? 8638736
关于积分的说明 18319342
捐赠科研通 6399854
什么是DOI,文献DOI怎么找? 3083500
关于科研通互助平台的介绍 2129801
邀请新用户注册赠送积分活动 2060295